CD44 and acute myeloid leukemia: We initially tested the potential of defactinib to reduce pFAK in AML cells and found that after an 18 h incubation followed by 3 h on the BMAS (with and without anti-CD44), defactinib reduced pFAK in both adhered and non-adhered AML cells (p = 0.039; Figure 5f).